{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:33:07Z","timestamp":1790346787220,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,8]]},"DOI":"10.7759\/cureus.44914","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T17:29:06Z","timestamp":1694194146000},"source":"Crossref","is-referenced-by-count":5,"title":["Retrospective Analysis of Liver Enzyme Abnormalities in Patients Prescribed Terbinafine and Itraconazole for Onychomycosis"],"prefix":"10.7759","author":[{"given":"Fatma","family":"Etg\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2022.0186","article-title":"The accuracy of clinical diagnosis of onychomycosis in Dutch general practice: a diagnostic accuracy study","author":"Watjer RM","year":"2023","unstructured":"Watjer RM, Bonten TN, Arkesteijn MA, et al.. The accuracy of clinical diagnosis of onychomycosis in Dutch general practice: a diagnostic accuracy study. BJGP Open. 2023, 10.3399\/BJGPO.2022.0186","journal-title":"BJGP Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_160_18","article-title":"Clinicomycological and histopathological profile of onychomycosis: a cross-sectional study from South India","volume":"64","author":"Chetana K","year":"2019","unstructured":"Chetana K, Menon R, David BG, Ramya MR. Clinicomycological and histopathological profile of onychomycosis: a cross-sectional study from South India. Indian J Dermatol. 2019, 64:272-6. 10.4103\/ijd.IJD_160_18","journal-title":"Indian J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_360_2022","article-title":"Prevalence of onychomycosis in patients with diabetes mellitus: a cross-sectional study from a tertiary care hospital in North India","volume":"89","author":"Agrawal S","year":"2023","unstructured":"Agrawal S, Singal A, Grover C, Das S, Arora VK, Madhu SV. Prevalence of onychomycosis in patients with diabetes mellitus: a cross-sectional study from a tertiary care hospital in North India. Indian J Dermatol Venereol Leprol. 2023, 89:710-7. 10.25259\/IJDVL_360_2022","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-016-0078-4","article-title":"Tinea unguium: diagnosis and treatment in practice","volume":"182","author":"Asz-Sigall D","year":"2017","unstructured":"Asz-Sigall D, Tosti A, Arenas R. Tinea unguium: diagnosis and treatment in practice. Mycopathologia. 2017, 182:95-100. 10.1007\/s11046-016-0078-4","journal-title":"Mycopathologia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2021.03.019","article-title":"A descriptive study of onychoscopic features in various subtypes of onychomycosis","volume":"78","author":"Devi Sangeetha A","year":"2022","unstructured":"Devi Sangeetha A, Gopalakrishnan K, Ramachandran R, Narasimhan M, Ramraj B. A descriptive study of onychoscopic features in various subtypes of onychomycosis. Med J Armed Forces India. 2022, 78:S219-25. 10.1016\/j.mjafi.2021.03.019","journal-title":"Med J Armed Forces India"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.637216","article-title":"Diagnosis of onychomycosis: from conventional techniques and dermoscopy to artificial intelligence","volume":"8","author":"Lim SS","year":"2021","unstructured":"Lim SS, Ohn J, Mun JH. Diagnosis of onychomycosis: from conventional techniques and dermoscopy to artificial intelligence. Front Med (Lausanne). 2021, 8:10.3389\/fmed.2021.637216","journal-title":"Front Med (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/1872213X13666191026090713","article-title":"Onychomycosis: an updated review","volume":"14","author":"Leung AK","year":"2020","unstructured":"Leung AK, Lam JM, Leong KF, Hon KL, Barankin B, Leung AA, Wong AH. Onychomycosis: an updated review. Recent Pat Inflamm Allergy Drug Discov. 2020, 14:32-45. 10.2174\/1872213X13666191026090713","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010031.pub2","article-title":"Oral antifungal medication for toenail onychomycosis","volume":"7","author":"Kreijkamp-Kaspers S","year":"2017","unstructured":"Kreijkamp-Kaspers S, Hawke K, Guo L, et al.. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017, 7:CD010031. 10.1002\/14651858.CD010031.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","article-title":"Onychomycosis: current trends in diagnosis and treatment","volume":"88","author":"Westerberg DP","year":"2013","unstructured":"Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013, 88:762-70.","journal-title":"Am Fam Physician"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2044511","article-title":"Optimal diagnosis and management of common nail disorders","volume":"54","author":"Lee DK","year":"2022","unstructured":"Lee DK, Lipner SR. Optimal diagnosis and management of common nail disorders. Ann Med. 2022, 54:694-712. 10.1080\/07853890.2022.2044511","journal-title":"Ann Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.03.021","article-title":"The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis","volume":"120","author":"Chang CH","year":"2007","unstructured":"Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007, 120:791-8. 10.1016\/j.amjmed.2007.03.021","journal-title":"Am J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16394","article-title":"Onychomycosis: a review","volume":"34","author":"Gupta AK","year":"2020","unstructured":"Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020, 34:1972-90. 10.1111\/jdv.16394","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1829592","article-title":"Safety of current therapies for onychomycosis","volume":"19","author":"Ricardo JW","year":"2020","unstructured":"Ricardo JW, Lipner SR. Safety of current therapies for onychomycosis. Expert Opin Drug Saf. 2020, 19:1395-408. 10.1080\/14740338.2020.1829592","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1270264","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis I","year":"2017","unstructured":"Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017, 16:149-65. 10.1080\/14740338.2017.1270264","journal-title":"Expert Opin Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben A","year":"2010","unstructured":"Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010, 52:2065-76. 10.1002\/hep.23937","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i8.601","article-title":"Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database","volume":"6","author":"Raschi E","year":"2014","unstructured":"Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014, 6:601-12. 10.4254\/wjh.v6.i8.601","journal-title":"World J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.172","article-title":"Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis","volume":"84","author":"Wang Y","year":"2021","unstructured":"Wang Y, Geizhals S, Lipner SR. Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis. J Am Acad Dermatol. 2021, 84:497-9. 10.1016\/j.jaad.2020.04.172","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-014-9969-y","article-title":"Systematic review of severe acute liver injury caused by terbinafine","volume":"36","author":"Yan J","year":"2014","unstructured":"Yan J, Wang X, Chen S. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm. 2014, 36:679-83. 10.1007\/s11096-014-9969-y","journal-title":"Int J Clin Pharm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3578","article-title":"Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections","volume":"154","author":"Stolmeier DA","year":"2018","unstructured":"Stolmeier DA, Stratman HB, McIntee TJ, Stratman EJ. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections. JAMA Dermatol. 2018, 154:1409-16. 10.1001\/jamadermatol.2018.3578","journal-title":"JAMA Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1708242","article-title":"Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration","volume":"32","author":"Wang Y","year":"2021","unstructured":"Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. J Dermatolog Treat. 2021, 32:783-7. 10.1080\/09546634.2019.1708242","journal-title":"J Dermatolog Treat"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: treatment and prevention of recurrence","volume":"80","author":"Lipner SR","year":"2019","unstructured":"Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019, 80:853-67. 10.1016\/j.jaad.2018.05.1260","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0163-4453(91)90954-q","article-title":"The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B","volume":"22","author":"van't Wout JW","year":"1991","unstructured":"van't Wout JW, Novakova I, Verhagen CA, Fibbe WE, de Pauw BE, van der Meer JW. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect. 1991, 22:45-52. 10.1016\/0163-4453(91)90954-q","journal-title":"J Infect"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-6-200109180-00010","article-title":"Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial","volume":"135","author":"Boogaerts M","year":"2001","unstructured":"Boogaerts M, Winston DJ, Bow EJ, et al.. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001, 135:412-22. 10.7326\/0003-4819-135-6-200109180-00010","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"25","author":"Girois SB","year":"2006","unstructured":"Girois SB, Chapuis F, Decullier E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2006, 25:138-49. 10.1007\/s10096-005-0080-0","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01657-09","article-title":"Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection","volume":"54","author":"Wang JL","year":"2010","unstructured":"Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010, 54:2409-19. 10.1128\/AAC.01657-09","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12178","article-title":"Risk of oral antifungal agent-induced liver injury in Taiwanese","volume":"77","author":"Kao WY","year":"2014","unstructured":"Kao WY, Su CW, Huang YS, et al.. Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol. 2014, 77:180-9. 10.1111\/bcp.12178","journal-title":"Br J Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6746989","article-title":"Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats","volume":"2017","author":"Khoza S","year":"2017","unstructured":"Khoza S, Moyo I, Ncube D. Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats. J Toxicol. 2017, 2017:6746989. 10.1155\/2017\/6746989","journal-title":"J Toxicol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.06.016","article-title":"A pharmacovigilance study of terbinafine indication and liver enzyme elevation","volume":"8","author":"Arcuri D","year":"2022","unstructured":"Arcuri D, Laga\u00e7e F, Sassevile D, Litvinov IV. A pharmacovigilance study of terbinafine indication and liver enzyme elevation. JAAD Int. 2022, 8:114-5. 10.1016\/j.jdin.2022.06.016","journal-title":"JAAD Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/182527-retrospective-analysis-of-liver-enzyme-abnormalities-in-patients-prescribed-terbinafine-and-itraconazole-for-onychomycosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:50Z","timestamp":1707509150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/182527-retrospective-analysis-of-liver-enzyme-abnormalities-in-patients-prescribed-terbinafine-and-itraconazole-for-onychomycosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.44914","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}